![Marc Bär](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Marc Bär is currently the Chairman at Malcisbo AG, Director at Kein & Aber AG, and Director at Medyria AG.
Previously, he worked as a Director at Julius Baer Holding AG from 1999 to 2005.
He was also a Principal at the University of Zurich in 1986 and a Member of the StartAngels Network.
Dr. Bär holds a doctorate degree from the University of Zurich, which he received in 1986, and an undergraduate degree, which he received in 1982.
Posizioni attive di Marc Bär
Società | Posizione | Inizio |
---|---|---|
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Presidente | - |
Medyria AG
![]() Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Direttore/Membro del Consiglio | - |
Kein & Aber AG
![]() Kein & Aber AG Publishing: Books/MagazinesConsumer Services Kein & Aber AG engages in publishing books. It publishes books, pocketbooks, electronic books, digital versatile disc's, gift books, and pics and picks. The company was founded by Peter George Haag on June 26, 1992 and is headquartered in Zurich, Switzerland. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Marc Bär
Società | Posizione | Fine |
---|---|---|
Julius Baer Holding AG | Direttore/Membro del Consiglio | 01/01/2005 |
University of Zurich | Corporate Officer/Principal | 01/01/1986 |
StartAngels Network
![]() StartAngels Network Packaged SoftwareTechnology Services StartAngels Network operates as a platform for business angel investors. Its angle investors invest directly in the start-up companies, coach them, and provide useful contacts. The company was founded by Peter H. Müller in 2000 and is headquartered in Zurich, Switzerland. | Corporate Officer/Principal | - |
Formazione di Marc Bär
University of Zurich | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Kein & Aber AG
![]() Kein & Aber AG Publishing: Books/MagazinesConsumer Services Kein & Aber AG engages in publishing books. It publishes books, pocketbooks, electronic books, digital versatile disc's, gift books, and pics and picks. The company was founded by Peter George Haag on June 26, 1992 and is headquartered in Zurich, Switzerland. | Consumer Services |
Julius Baer Holding AG | Finance |
StartAngels Network
![]() StartAngels Network Packaged SoftwareTechnology Services StartAngels Network operates as a platform for business angel investors. Its angle investors invest directly in the start-up companies, coach them, and provide useful contacts. The company was founded by Peter H. Müller in 2000 and is headquartered in Zurich, Switzerland. | Technology Services |
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
Medyria AG
![]() Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Marc Bär